A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus Clinical Trial

Official title:

A Double Blind, Placebo-Controlled, Randomized, Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01862939
• Other study ID #: DS7309-A-U101
• Status: Completed
• Phase: Phase 1
• First received: May 22, 2013
• Last updated: May 24, 2013
• Start date: April 2011
• Est. completion date: September 2011

Study information

• Verified date: May 2013
• Source: Daiichi Sankyo Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a randomized, placebo-controlled, 2-part, sequential, single ascending dose study.

Part 1 is planned as 6 sequential escalation treatment groups. Part 2 is a randomized, placebo-controlled, two-period sequential pharmacodynamic (PD) arm.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: September 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Women must be of non-child bearing potential, ie, either:

1. Surgically sterile (ie, bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to dosing), or

2. Naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to dosing, with a follicle stimulating hormone (FSH) level at screening of = 40 mIU/mL.

• All women must have a negative serum pregnancy test at screening and within 48 hours before dosing.

• Able to understand and willing to comply with all study requirements, and willing to follow the study medication regimen.

• Subjects must give written informed consent to participation in the study prior to screening.

• Negative urine test for drugs of abuse and alcohol at screening and check-in.

• Negative result for HIV antibody, hepatitis B surface antigen, and hepatitis C antibody at screening.

• Subjects must agree to abstain from alcohol, cola, tea, coffee, chocolate and other caffeinated drink and food from 2 days before check-in and throughout confinement.

• Subjects must agree to abstain from grapefruit/grapefruit juice and Seville oranges from 10 days before the first dose and throughout the study.

• Healthy women who are not of childbearing potential and men, 18 to 45 years of age, inclusive.

• Body Mass Index (BMI) of 19.00 to 32.00 kg/m2 inclusive.

• Good health, as determined by the absence of clinically significant deviation from normal, based on medical history, physical examination, laboratory reports, and 12-lead ECG, as deemed by the Investigator, prior to enrollment.

• Baseline (0 hour) pre-dose capillary blood glucose = 70 mg/dL. Part 2 (T2DM subjects)

• Women who are not of childbearing potential and men, 18 to 55 years of age, inclusive.

• Diagnosis of type 2 diabetes mellitus for a minimum of 3 months prior to first dose.

• Body Mass Index (BMI) of 19.00 to 40.00 kg/m2 inclusive.

• Subjects should be either:

1. Treatment naïve from any antidiabetic treatment for at least 6 months prior to screening with a hemoglobin A1c (HBA1c) value between 7%-10%, inclusive.

2. On metformin alone with a HBA1c value between 7%-9%, inclusive, and willing to discontinue current metformin treatment for at least 2 weeks prior to study and during the duration of the study. See Section 9.10.1 for monitoring during 2 week washout.

Exclusion Criteria:

• Female subject is of childbearing potential, is pregnant (as based on test results) or is breast feeding.

• Male subjects should ensure use of condom and spermicide from dosing until 12 weeks after dosing.

• Male subjects must agree not to donate sperm from dosing until 12 weeks after dosing.

• Any history of drug abuse.

• History of alcohol addiction during the 2 years prior to Day 1.

• History or current evidence, as determined by the Investigator, of psychiatric or emotional problems which would invalidate giving informed consent or limit the ability of the subject to comply with study requirements.

• History or current alcoholic or non-alcoholic liver disease or liver steatosis.

• History of neuropathy.

• Subjects with QTcF interval duration >450 msec obtained from the ECG taken at screening, after at least 10 minutes of quiet rest in a supine position.

• Subjects with a family history of long QT syndrome.

• Subjects with any history of arrhythmia.

• Significant blood donation or significant blood loss within the 56 days before Day -1.

• Plasma donation within 7 days before Day -1.

• Participation in another investigational new drug research study within the 30 days before Day 1.

• Use of tobacco products or nicotine-containing products (including smoking cessation aids, such as gums or patches) within the 6 months before Day 1.

• Relationship of the subject to the Investigator, any sub-investigator, pharmacist, study coordinator, or other staff directly involved in the conduct of the study, or employment by the Sponsor or contract research organization participating in the study.

• Familial relationship of the subject to any subjects previously or currently enrolled in the study.

• Screening laboratory values outside the range of normal values that are deemed clinically significant by the Investigator. Liver function tests (AST, ALT, total bilirubin, and lactate dehydrogenase [LDH]) must be at or below the ULN. If a subject has a non-clinically significant high abnormal reading for one or more of the liver function tests on the screening lab test, the test may be repeated once. If the lab test results are normal on the repeat test, he/she may be enrolled provided the Day -1 lab test results are also normal.

• Hemoglobin levels below the lower limit of normal of the clinical laboratory's reference range at the screening visit.

• Enrollment in a prior dose cohort of this study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• DS-7309
1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
• placebo
placebo to match part 2 DS-7309

Locations

Country	Name	City	State
United States	Celerion	Tempe	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Daiichi Sankyo Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	incremental area under the curve (IAUC) blood glucose	The incremental area under the curve (IAUC) of the PD biomarker blood glucose following an oral glucose tolerance test (OGTT) in subjects with type 2 diabetes mellitus (T2DM).	5 hours	No
Secondary	determine blood concentrations of DS-7309	The plasma pharmacokinetic (PK) parameters of A203-5319 (the free form of DS-7309) and relevant metabolite of DS-7309 in healthy subjects and subjects with T2DM.	48 hours	No